Form D · Biotechnology
Steep Hill, Inc.
Berkeley, CA · CIK 0001649526
Offering snapshot reported Jul 10, 2019 · SEC filing
- Reported sold
- $4.07M Offering amount: $4.07M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 25, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 10, 2019 | Initial | $4,069,052 | No comparison | 18 | SEC filing |
| Jul 10, 2019 | Initial | $4,000,000 | No comparison | 14 | SEC filing |
| Apr 3, 2017 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Aug 25, 2015 | Initial | $1,000,050 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-343907
Source: Form D, filed Jul 10, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mitchell Baruchowitz | Director |
| Stephen De Angelo | Director |
| Addison Demoura | Director |
| Stephen Finfer | Director |
| Brett Finkelstein | Director |
| Jmichaele Keller | Director, Executive |
| Mitchell Kulick | Executive |
| David Lampach | Director, Executive |
| Jeffrey Monat | Director |
| Andrew Rosenstein | Executive |
| Nigel Stobart | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1005 Parker Street
Berkeley, CA, 94710
Berkeley, CA, 94710